GSKNYSEPharmaceutical PreparationsAlso trades as GLAXF
GSK plc
Financials through fiscal 2025, year ended Dec 31, 2025
$49.46−0.05 (-0.10%)
Close on Oct 19, 2026
Share price
+$5.55 (+12.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividend
GSK plc grew revenue 4.1% to £32.67B over fiscal 2025. Operating income rose 97.3% to £7.93B, moving the operating margin from 12.8% to 24.3%. Free cash flow was £6.39B, up 24.0% from a year earlier.
Revenue
£32.67B
+4.1% vs. a year earlier
Operating income
£7.93B
+97.3% vs. a year earlier
Free cash flow
£6.39B
+24.0% vs. a year earlier
EPS, diluted
1.39 GBP
+123.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- £32.67B
- Net income
- £5.72B
- EPS, diluted
- 1.39 GBP
- Free cash flow
- £6.39B
Valuation needs the share price. It fills in once daily prices are connected and converted from GBP.
Eleven years at a glance
Fiscal years 2015 to 2025, GBP
Revenue
£32.67B+4.1% YoY
Gross profit
£23.65B+5.9% YoY
Operating income
£7.93B+97.3% YoY
Net income
£5.72B+122.0% YoY
EPS, diluted
1.39 GBP+123.2% YoY
Free cash flow
£6.39B+24.0% YoY
Reported period